Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system
Regulatory T cells in the control of inflammatory demyelinating diseases of the central nervous system
复制标题
DOI：
10.1097/wco.0b013e3282febf58
复制
发表时间：
2008-06-01
影响因子：
4.8
通讯作者：
Liblau, Roland S.
中科院分区：
文献类型：
--
作者：
Anderton, Stephen M.;Liblau, Roland S.
综述目的基础免疫学的新概念，特别是具有调节特性的 CD4 T 细胞谱系的鉴定，彻底改变了对实验模型和人类中免疫介导疾病的理解。最近的研究结果正在临床前动物模型中积极研究以 CD25 和 Foxp3 转录因子的表达为特征的 T 调节细胞对中枢神经系统炎症的发展和缓解及其治疗潜力的影响。最近的数据表明，CD4(+)CD25(+)foxp3(+) T 调节细胞在实验性自身免疫性脑脊髓炎期间在次级淋巴器官水平和发炎的中枢神经系统中发挥作用。它们有助于针对自身免疫的自然保护并参与疾病的自发缓解。它们在多发性硬化症中的作用仍不清楚，但趋同数据表明来自多发性硬化症患者的循环CD4(+)CD25(+) T细胞表现出有缺陷的调节特性。几种疾病缓解疗法作用于 T 调节细胞，其对多发性硬化症的有益作用可能部分源于这种作用模式。总结更好地了解 T 调节细胞的诱导、其作用机制以及体内操纵它们的方法可能为多发性硬化症患者提供新的治疗机会。
Purpose of review New concepts in fundamental immunology, in particular the identification of a lineage of CD4 T cells endowed with regulatory properties, have revolutionized the understanding of immune-mediated diseases both in experimental models and in humans.Recent findingsThe impact of the T regulatory cells, characterized by the expression of CD25 and the foxp3 transcription factor, on the development and remission from central nervous system inflammation, and their therapeutic potential, is being aggressively studied in preclinical animal models. Recent data indicate that the CD4(+)CD25(+)foxp3(+) T regulatory cells act both at the level of secondary lymphoid organs and in the inflamed central nervous system during experimental autoimmune encephalomyelitis. They contribute to the natural protection against autoimmunity and participate in the spontaneous remission of disease. Their role in multiple sclerosis is still unclear, but convergent data indicate that circulating CD4(+)CD25(+) T cells from patients with multiple sclerosis exhibit defective regulatory properties. Several disease-modifying therapies act on T regulatory cells and their beneficial effects on multiple sclerosis could, in part, result from this mode of action.SummaryA better understanding of the induction of T regulatory cells, of their mechanisms of action, and of approaches to manipulate them in vivo may offer new therapeutic opportunities for patients with multiple sclerosis.